June 30, 2025
By

Nilestrept for Poultry: Treatment for Colibacillosis & Airsacculitis

Nilestrept is a veterinary antibiotic product offered by Boston Vet, specifically formulated for use in poultry to combat serious bacterial infections such as colibacillosis, airsacculitis, fowl cholera, and coryza. Each milliliter of Nilestrept contains Streptomycin Sulphate, a potent aminoglycoside antibiotic known for its effectiveness against a broad spectrum of bacterial pathogens affecting poultry. 

Key Uses of Nilestrept in Poultry 

  • Colibacillosis: This disease, caused by avian pathogenic Escherichia coli (APEC), is one of the most economically damaging bacterial infections in poultry worldwide. Streptomycin, the active ingredient in Nilestrept, has demonstrated efficacy in treating colibacillosis, especially when susceptibility testing supports its use. 

 

  • Airsacculitis: A respiratory condition often linked to bacterial infections including E. coli, airsacculitis causes inflammation of the air sacs in birds. Nilestrept’s antibacterial action helps reduce bacterial load and inflammation, aiding in recovery. 
  • Fowl Cholera and Coryza: Both are infectious diseases affecting poultry respiratory systems. Streptomycin’s broad antibacterial spectrum makes Nilestrept a valuable option for managing these infections. 

Advantages of Using Nilestrept 

  • Research has shown that Nilestrept is bioequivalent to established streptomycin formulations, ensuring effective therapeutic levels in poultry after administration. 

 

  • Streptomycin targets a wide range of bacterial pathogens responsible for respiratory and systemic infections in poultry, making Nilestrept a versatile treatment choice. 

 

  •  By effectively treating infections like colibacillosis and airsacculitis, Nilestrept helps reduce mortality and economic losses in poultry operations. 

 

 

Nilestrept stands as an effective injectable antibiotic for treating critical bacterial diseases in poultry including colibacillosis, airsacculitis, fowl cholera, and coryza. Supported by bioequivalence studies and clinical efficacy.